U.S. Intravenous Immunoglobulin Market, by Formulation (Liquid and Powder), by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy,

U.S. Intravenous Immunoglobulin Market, by Formulation (Liquid and Powder), by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Intravenous immune globulin (IVIG) is an antibody-based product that can be administered intravenously (through a vein). Intravenous immunoglobulin (IVIG) is a blood product made from the serum of 1,000 to 15,000 donors per batch. It is a preferred treatment for the patients with antibody deficiencies. For this indication, IVIG is administered at a 'replacement dose' of 200–400 mg/kg body weight every three weeks.

Market Dynamics

Market players are involved in getting their products approved from regulatory authorities, which would contribute to the growth of the U.S. intravenous immunoglobulin market over the forecast period. For instance, on February 11, 2021, CSL Behring, a global biotherapeutics leader, announced that the U.S. Food and Drug Administration (FDA) designated Privigen (Immune Globulin Intravenous (Human), 10% Liquid) as an orphan-drug for the treatment of Systemic Sclerosis (SSc).

Market players and government authorities are involved in expanding their global presence by adopting strategies such as acquisitions and collaborations, which is expected to drive the growth of the U.S. intravenous immunoglobulin market. For instance, on April 27, 2021, Kamada Ltd. and Kedrion Biopharma, two prominent bio-pharmaceutical companies specializing in plasma-derived protein therapeutics, announced a global collaboration for the development, manufacturing, and distribution of a human plasma-derived Anti-SARS-CoV-2 (COVID-19) polyclonal immunoglobulin (IgG) product as a potential coronavirus treatment.

Increasing product launches and approvals is expected to boost the growth of US intravenous immunoglobulin market over the forecast period. For instance, on April 01, 2019, ADMA Biologics, Inc., a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company, announced that the US Food and Drugs Administration (FDA) approved ASCENIV, Immune Globulin Intravenous, Human, 10% Liquid, formerly known as RI-002. ASCENIV is an Intravenous Immune Globulin (IVIG) drug product used to treat adults and adolescents with primary humoral immunodeficiency disease (PIDD or PI).

Key features of the study:
This report provides an in-depth analysis of U.S. intravenous immunoglobulin market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the U.S. intravenous immunoglobulin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include Biotest AG, Octapharma AG, Grifols S.A., Kedrion Biopharma, Inc., CSL Behring, McKesson Corporation, Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Pfizer, Inc. and ADMA Biologics, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The U.S. intravenous immunoglobulin market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the U.S. intravenous immunoglobulin market
Detailed Segmentation:
U.S. Intravenous Immunoglobulin Market, By Formulation:
Liquid
Powder
U.S. Intravenous Immunoglobulin Market, By Application :
Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary Immunodeficiency Diseases
Myasthenia Gravis
Multifocal Motor Neuropathy
Kawasaki Disease
Others
U.S. Intravenous Immunoglobulin Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Company Profiles
Biotest AG *
Company Overview
Product Portfolio
Financial Performance
Recent Developments/Updates
Strategies
Octapharma AG
Grifols S.A.
Kedrion Biopharma, Inc.
CSL Behring
McKesson Corporation
Takeda Pharmaceutical Company Limited
Bio Products Laboratory Ltd.
Pfizer, Inc.
ADMA Biologics, Inc.
“*” marked represents similar segmentation in other categories in the respective section.